Sivelestat

Sivelestat

SCHEMBL4411778

CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-])cc1.[Na+]

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ELANE

The experimentally established mechanism targets of Sivelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ELANE known ✓ P08246 16/20 0.69
PRTN3 P24158 12/20 0.69
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
NPC1 O15118 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KCNA5 P22460 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sivelestat SCHEMBL29677633 1.00 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL29490347 0.99 ELANE (0.68) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL7107254 0.99 ELANE (0.68) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL28751433 0.91 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
SCHEMBL7267891 0.91 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL4411781 0.91 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL123221 0.91 ELANE (0.71) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL6690886 0.90 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
SCHEMBL9777074 0.90 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10
Sivelestat SCHEMBL30864380 0.90 ELANE (0.69) ELANEPRTN3KDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638556-B2 Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-29 US claimed
US-20070203357-A1 FREEZE-DRIED PRODUCT OF N-[O-(P-PIVALOYLOXY BENZENESULFONYLAMINO) BENZOYL]GLYCINE MONOSODIUM SALT TETRA-HYDRATE AND A PROCESS FOR THE MANUFACTURE THEREOF ONO PHARMACEUTICAL CO., LTD. 2007-08-30 US claimed
EP-1393727-B1 REMEDIAL AGENT FOR MYELOPATHIC DISEASE ONO PHARMACEUTICAL CO (JP) 2007-04-18 EP claimed
US-20050101633-A1 Remedial agent for myelopathic disease ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US claimed
US-20040092587-A1 Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 US claimed
EP-1393727-A1 REMEDIAL AGENT FOR MYELOPATHIC DISEASE ONO PHARMACEUTICAL CO., LTD. (JP) 2004-03-03 EP claimed
EP-1166773-B1 Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof ONO PHARMACEUTICAL CO (JP) 2004-02-11 EP claimed
US-6624193-B1 Prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula phenylcarboxylate amidesulfonamide ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-23 US claimed
EP-1304106-A1 FREEZE-DRIED PREPARATION OF N- o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-23 EP claimed
US-6552082-B2 Solubility makes it possible to manufacture a solution of higher concentration of the compound and high-dosage drug product ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US claimed
EP-1213018-A1 PREVENTIVE AND THERAPEUTIC AGENTS FOR EYE DISEASES ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-12 EP claimed
US-20020022738-A1 Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2002-02-21 US claimed
EP-1166773-A1 Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2002-01-02 EP claimed
JP-9040692-A None JP disclosed
EP-3403673-B1 COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP) 2023-10-11 EP disclosed
CN-116635018-A Pharmaceutical composition for inhalation 上海汇伦医药股份有限公司 2023-08-22 CN disclosed
US-5359121-A N-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine benzyl ester; elastase inhibitor; useful for treatment of emphysema, atherosclerosis, rheumatoid arthritis ONO PHARMACEUTICAL CO., LTD. (JP) 1994-10-25 US disclosed
US-5359121-A N-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine benzyl ester; elastase inhibitor; useful for treatment of emphysema, atherosclerosis, rheumatoid arthritis ONO PHARMACEUTICAL CO., LTD. (JP) 1994-10-25 US disclosed
EP-0539223-A1 Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase ONO PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 EP disclosed
EP-0539223-A1 Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase ONO PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203357-A1 FREEZE-DRIED PRODUCT OF N-[O-(P-PIVALOYLOXY BENZENESULFONYLAMINO) BENZOYL]GLYCINE MONOSODIUM SALT TETRA-HYDRATE AND A PROCESS FOR THE MANUFACTURE THEREOF SLC6A5, SLC6A9, SLC6A6 ELANE 3536/4885PRTN3 3806/4885KDM4E 2738/4885
US-20020022738-A1 Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof SLC6A5, ABCB11, SLC6A1 ELANE 4496/4885PRTN3 3836/4885KDM4E 1108/4885
US-20040092587-A1 Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same SLC6A5, SI, PFAS ELANE 3459/4885PRTN3 3551/4885KDM4E 1628/4885
US-20050101633-A1 Remedial agent for myelopathic disease NR1H2, MSR1, NR1H3 ELANE 2565/4885PRTN3 382/4885KDM4E 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.